Bone Disorders

Less Pain Post TKA With Addition of Peripheral Nerve Blocks

April 19, 2018

The researchers found that intervention patients reported lower numeric rating scale pain scores on ambulation than the control group on postoperative day (POD) one (1.7 versus 5.0; P <.001).

Crysvita Approved for the Treatment of X-Linked Hypophosphatemia

By April 17, 2018

Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.

Pre-Op Chronic Opioid Use Ups Poor Outcomes Post Spinal Fusion

April 02, 2018

The researchers found that 22.3% of patients had documented opioid use for more than 6 months before surgery, and 87.4% of these had continued long-term use postoperatively.

Abaloparatide Followed by Alendronate Ups BMD in Postmenopausal Women

By March 19, 2018

At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.

Year-Long Study Assesses Opioid vs. Non-Opioid Tx for Back, Osteoarthritis Pain

March 07, 2018

The researchers observed no significant difference between the groups in pain-related function over 12 months (overall P=0.58); the mean 12-month Brief Pain Inventory (BPI) interference was 3.4 and 3.3 for the opioid and non-opioid groups, respectively.

Benefits of Rivaroxaban, Aspirin Compared After Hip, Knee Arthroplasty

February 22, 2018

The researchers found that venous thromboembolism occurred in 0.64 and 0.7% of patients in the aspirin and rivaroxaban groups, respectively (difference, 0.06 percentage points; 95% confidence interval [CI], −0.55 to 0.66; P<0.001 for noninferiority and P=0.84 for superiority).

Treating Endothelial Function May Target Root Disease in Marfan Syndrome

February 13, 2018

The researchers found that the MFS/ATR1a-null mice showed unabated aortic root enlargement and remained responsive to losartan, despite being hypotensive and resistant to AngII vasopressor effects.

Does Long-Term ICS Use Increase Fracture Risk in COPD Patients?

By February 05, 2018

Long-term ICS exposure at high doses was associated with a modest but significant increase in the risk of hip or upper extremity fractures.

Psychoactive Drug Prescribing Linked to Nursing Facility Hip Fractures

January 29, 2018

In combination, state and facility characteristics explained 6.7% of the variation in hip fracture, and resident characteristics accounted for 7.6% of the variation.

USPSTF Updates Recommendation Statement on Scoliosis Screening

January 10, 2018

"Our review of the current evidence has pointed to more questions than answers about the benefits and harms of screening children and teenagers with no symptoms of scoliosis," said USPSTF member Alex R. Kemper, MD, MPH.

Do Vitamin D, Calcium Supplements Cut Fracture Risk in Older Patients?

By December 26, 2017

Thirty-three randomized trials (n=51,145) were identified that met the inclusion criteria.

Steroid Injection Site Linked to Bone Changes in Osteoarthritis Patients

By November 29, 2017

Their results found that 22-24% of the hip injection group had new osteonecrosis vs. 5-9% of the hip control group and to 5% of the shoulder injection group.

Does Inhaled Corticosteroid Use Up the Risk of Fracture in Children?

November 14, 2017

Inhaled corticosteroids are not associated with increased odds of fracture in the pediatric asthma population

USPSTF Issues Recommendations for Osteoporosis Screening

November 08, 2017

Screening for osteoporosis with bone measurement testing should also occur in postmenopausal women <65 years who are at increased risk of osteoporosis as determined by a formal clinical risk assessment tool (B recommendation).

CombiPatch, Minivelle Patches No Longer in Shortage

By October 03, 2017

Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.

Romosozumab Followed by Alendronate Superior in Reducing Fracture Risk

By September 12, 2017

ARCH (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture) was a multicenter, international, randomized, double-blind, alendronate-controlled study (n=4,093) in postmenopausal women with osteoporosis at high risk for fracture based on previous fracture history.

Fracture Risk Reduced with Abaloparatide Followed by Alendronate

By September 11, 2017

The data showed a statistically significant fracture risk reduction through 3.5 years.

Alendronate Safe, Effective in Elderly Patients with Prior Fracture

September 07, 2017

Alendronate treatment reduced risk of hip fracture with sustained safety

Necessity of Opioid Rx Examined Post-Hernia Repair

August 15, 2017

The researchers found that 85.9% of patients reported using four or fewer opioid tablets, with 59.5% reporting that they used no opioid analgesics postoperatively.

Osteoporosis Drugs Assessed for Secondary Fracture Prevention

By August 10, 2017

Results showed a significant reduction in the risk for secondary vertebral fracture with all of the of anti-osteoporotic drugs (risk ratio [RR] 0.38-0.77).

Osteoporosis Med Efficacy Assessed in Nonmetastatic Prostate CA

August 09, 2017

The researchers found that BMD was effectively increased with bisphosphonates, but no trial was sufficiently powered to detect a decrease in fractures.

Vitamin B Effects on Fracture Risk Examined in Women at High CVD Risk

August 07, 2017

The researchers found that B vitamin supplementation had no significant effect on non-spine fracture risk (relative hazard, 1.08; 95% confidence interval, 0.88 to 1.34).

FDA Requests More Data for Unique Osteoporosis Drug Candidate

By July 17, 2017

Dr. Pascale Richetta, head of bone and executive vice president, UCB, stated, "With all three pivotal romosozumab Phase 3 studies now included in the clinical evidence package, representing data from more than 11,000 patients, we are committed to bringing this important potential new treatment to those people living at risk of fragility fractures."

Research Paper Reviews JFK's Chronic Health Issues

By July 14, 2017

A new review published in the Journal of Neurosurgery: Spine details the health issues that troubled JFK the most, specifically his back. His low-back pain was instigated by a football injury sustained while he was at Harvard in 1937. An orthopedic spine specialist diagnosed him in 1940 with a "very unstable lumbosacral joint".

Early ART Start Linked to Bone Loss in HIV Patients

By June 27, 2017

Over the 2.2 years mean follow-up, the immediate ART arm demonstrated greater BMD declines vs. the deferred ART arm at the hip (-2.5% vs. -1.0%, 95% CI: -2.2 to -0.8; P<0.001) and at the spine (-1.9% vs. -0.4%, 95% CI: -2.2 to -1.0; P<0.001).

Pooled Safety Analysis Finds Jardiance Well Tolerated

By June 14, 2017

The proportion of study patients with lower limb amputations were similar for Jardiance (1.9%) and placebo groups (1.8%).

Do Certain B-Vitamins Increase Hip Fracture Risk?

June 12, 2017

But no significant link for vitamin B12 and risk of hip fracture during trial and extended follow-up

Antidepressant Linked to Accelerated Bone Loss

June 06, 2017

The researchers found that during venlafaxine treatment there was an increase in CTX and a decrease in P1NP, which was consistent with accelerated bone loss.

Mylan Launches Generic Reclast

By June 02, 2017

Reclast is also indicated to increase bone mass in men with osteoporosis; for the treatment of Paget's disease of bone (men and women); and for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women expected to be on glucocorticoids for at least 12 months.

AACE/ACE: New ACP Osteoporosis Guidelines 'Fall Short'

By May 19, 2017

Five important differences were identified by AACE/ACE involving pharmacotherapy choice as well as treatment duration and reevaluation.